The collaboration aims at automating the processing of up to 96 liquid biopsy samples at one time using Enable Bio's (ADAP) technology for immunoassays.
The test will combine Qiagen's QuantiFeron (interferon-gamma release assay) technology with DiaSorin's Liaison automated analyzers.
The collaboration between 15 federal and state groups used a workshop format originally developed by CDC to help other countries with their One Health issues.
The test is immunoassay-based and detects multiple targets using the firm's automated testing system called the BioPlex 2200.
Bluejay said that the collaboration will focus on the study of antigens associated with various pathogens and identifying the most immunoreactive antigen.
The company also reaffirmed fiscal fourth quarter growth expectations including double-digit growth in the US for its TB testing products.
The firm has added two new targets to make the Sofia 2 POC Lyme+ Fluorescent Immunoassay more relevant to Lyme disease pathogens in Europe.
ChromaCode this week launched its first product, a research-use-only test for nine tick-borne pathogens designed for research use on any thermal cycler.
The researchers are using mass spectrometry to look in patient blood samples for peptides shed by Borrelia burgdorferi, the bacteria that causes Lyme disease.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.